RedHill Biopharma Increases Patient Access to Talicia with EnvisionRx Formularies

Talicia is the first and only FDA-approved rifabutin-based therapy for H. pylori infection designed as a first-line option to address the high and growing resistance of H. pylori to clarithromycin-based therapies

Talicia is targeting an estimated two million U.S. patients treated annually for H. pylori infection

H. pylori bacterial infection is a Group 1 carcinogen and the strongest risk factor for gastric cancer; H. pylori affects approximately 35% of the U.S. population

EnvisionRx is a pharmacy benefit manager (PBM), serving more than 3.5 million members nationally

TEL-AVIV, Israel and RALEIGH, N.C., July 27, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that EnvisionRx, a Pharmacy Benefit Manager (PBM) and division of EnvisionRxOptions, a wholly owned subsidiary of Rite Aid, added Talicia (omeprazole magnesium, amoxicillin and rifabutin)¹ to its Formularies, as the unrestricted branded agent for H. pylori treatment, effective July 1, 2020.

“The addition of Talicia to the EnvisionRx national formularies as the unrestricted brand will allow its 3.5 million members nationally to gain access to Talicia. We continue to work diligently to further expand patient access to Talicia, the first and only FDA-approved rifabutin-based therapy for the treatment of H. pylori infection,” said Rick Scruggs, RedHill’s Chief Commercial Officer. “Despite the ongoing limitations due to the COVID-19 pandemic, our dedicated sales reps are back in the field, continuing their engagements with health care providers. We look forward to working closely with our partners to increase the availability of Talicia to more patients.” 

About Talicia
Talicia is the only rifabutin-based therapy approved for the treatment of H. pylori infection and is designed to address the high resistance of H. pylori bacteria to clarithromycin-based standard-of-care therapies. The high rates of H. pylori resistance to clarithromycin have led to significant rates of treatment failure with clarithromycin-based standard-of-care therapy and are a strong public health concern, as highlighted by the FDA and the World Health Organization (WHO) in recent years.